Erythema nodosum is an inflammatory disorder characterized by tender erythematous nodules. Causes of erythema nodosum include inflammatory bowel disease and other autoimmune disorders, infections, leukaemia and certain drugs.
Erythema nodosum is an inflammation of subcutaneous fat layers . The lesions are deep, tender nodules most commonly seen on the shins, but may occur on any part of the body  . They are usually more palpable than visible .
The lesions of erythema nodosum begin as red, tender nodules with poorly defined borders . They vary in size from 2 to 6 cm. Lesions last about 2 weeks with new lesions appearing for months . Lesions heal without any scaring .
Fifty percent of patients with erythema nodosum also have generalized arthralgia which usually precedes the rash . Erythema, swelling, and tenderness of any joint, sometimes with effusions, may occur. Ankles, knees, and wrist are the most common sites. Joint and leg pain and stiffness may last for up to 6 months. Synovial fluid and rheumatoid factor are negative and there are no damaging changes to the joints  .
The relapse rate has been reported to be as high as 74% in idiopathic erythema nodosum , but rarely in patients whose disease is secondary to an underlying disease  .
There are no specific tests for erythema nodosum. The following laboratory studies may be helpful:
Intradermal skin tests for tuberculosis, Yersinia, and coccidioidomycosis. Positive tuberculin test occurred in almost 50% of cases  .
Most cases of erythema nodosum are self-limited and require only treatment of the symptoms using non-steroidal anti-inflammatory medications (NSAIDs), cool compresses, elevation, and bed rest . Activity should be restricted in the acute phase when pain and swelling are significant .
If a drug reaction is suspected, it should be eliminated. Corticosteroids may be effective but are not usually necessary or recommended . Oral corticosteroids are effective, but only temporarily . Associated adverse effects of these drugs restrict their use to severe cases for short term use. Recurrence of erythema nodosum following discontinuation of treatment is common, and underlying infectious disease may be worsened .
Intralesion corticosteroids can be effective some cases .
Oral saturated solution of potassium iodide and colchicine, in patients unresponsive to non-steroidal anti-inflammatory drugs, have been shown to be effective . Treatment of the underlying trigger is imperative and may result in rapid resolution of erythema nodosum .
Erythema nodosum is generally benign and resolves without complications. The duration of symptoms can be extensive, lasting up to six months.
Erythema nodosum is one of a group of common inflammatory diseases of the hypodermis . Its etiology is unknown, but it is considered to be a hypersensitivity reaction to a systemic trigger .
Erythema nodosum is itself a self-limited, benign disorder but can be due to a serious underlying disease that triggers its appearance. Triggers include granulomatous diseases, malignancy (lymphoma and leukemia), inflammatory bowel diseases, and severe infections .
The condition usually begins abruptly with flulike symptoms: fever, malaise, and general aches. These symptoms are followed by the painful rash within 1-2 days . Arthralgia may precede or accompany the rash. In cases associated with infection lesions heal in 1-2 months. Those due to active disease may last up to 6 months. In 30% of cases of idiopathic erythema nodosum, eruptions may last more than 6 months . Erythema nodosum is self-limited and resolves without sequelae .
Erythema nodosum may occur at any age. Peak incidence is between the ages of 18-34 years, but varies with etiology  .
Incidence rates vary widely by country, with a median rate of 2.4 cases per 10,000 per year . Erythema nodosum occurs more often in women, with a male-to-female ratio of 1:4  .
It has been theorized that erythema nodosum is due to a T-cell mediated response between common antigens and the skin , suggesting that genetic factors play a role in determining who will develop these cutaneous symptoms .
In erythema nodosum, approximately 50% of cases are idiopathic, where no definite etiology is found. Of the remaining cases, the most common etiologies are primary tuberculosis (18%)  , post-streptococcal infection (16%), sarcoidosis (12%), inflammatory bowel diseases (IBD) (4%), Behçet's disease (2%), and pregnancy (2%) . The numbers differ significantly in the pediatric population with 55 % due to infectious diseases (half from streptococcal infections) and 22% from non-infectious inflammatory diseases . None of the reported cases were from tuberculosis and only 22% of the patients had no associated disease .
Since inflammatory bowel disease often presents with erythema nodosum, the presence of this symptom should prompt healthcare providers to suspect an underlying inflammatory disease .
There is no clear means of preventing erythema nodosum since the exact cause is not known. Prevention of the underlying triggers for the disease may decrease its incidence. Prevention of streptococcal infections, tuberculosis, enterobacterial infections may be helpful.
Treatment and control of inflammatory diseases such as inflammatory bowel disease and Crohn disease may decrease the occurrence and recurrence of erythema nodosum, as well.
Erythema nodosum (EN) refers to an erythematous, nodular eruption that usually occurs on the extensor surfaces of the lower legs . It is generally an acute episodic condition, though chronic or recurrent erythema nodosum may occur .
Erythema nodosum is a self-limited disorder. Recovery is complete with no further complications or sequelae. Treatment is symptomatic for this disorder. However, treatment of the triggering mechanism, if known, needs to be instituted first .
What is erythema nodosum?
Erythema nodosum is an acute nodular rash causing red, tender raised areas on the anterior shins and occasionally on other surfaces of the body. It is a benign disorder and resolves within 2 weeks to several months without complications. However, though not serious itself, it may be triggered by serious underlying conditions such as: tuberculosis, strep infections, inflammatory bowel disease, drug reactions, or malignancy.
What are the symptoms?
The primary symptom of erythema nodosum is the distinctive nodular rash. It may be accompanied by flu-like symptoms, fever and malaise. A majority of patients with erythema nodosum also have arthralgia, painful joints, and stiffness.
What causes erythema nodosum?
The cause of erythema nodosum s is not fully understood. It is thought to be a hypersensitivity reaction triggered by an immune response to an antigen. This causes inflammation of the hypodermal fatty layer of the subcutaneous tissue.
Who gets erythema nodosum?
Anyone of any age can get erythema nodosum, though it is most frequent in people age 18 to 35 years. It occurs 2 to 4 times more often in women than men.
How is it diagnosed?
There is no specific test for erythema nodosum. It is diagnosed by the clinical symptoms, primarily the characteristic lesions, and patient history. Certain blood tests help to confirm the diagnosis. A biopsy of the lesions can confirm the diagnosis in some cases.
How is erythema nodosum treated?
Erythema nodosum is treated with non-steroidal anti-inflammatory medications, ibuprofen, aspirin, and naproxen, bed rest and cool compresses. In patients who do not respond to this treatment corticosteroids may be used. Treatment of the underlying trigger, if known, is essential in the treatment of this disorder.
What are the complications?
There are no significant complications to erythema nodosum, though because of its long duration and the need for rest and decreased activity it does interfere with daily activities and quality of life. The underlying disease triggering erythema nodosum may have significant complications and even be life threatening.